+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Urinary Excretion of Aquaporin-2 Water Channel in Diabetic Ketoacidosis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We studied the changes in plasma arginine vasopressin (AVP) and urinary excretion of aquaporin-2 (UAQP-2) water channel in 3 patients with diabetic ketoacidosis. They had marked hyperglycemia of 27.9 ± 2.8 mmol/l (mean ± SEM), and elevated hemoglobin A1c of 8.8 ± 1.4%. Circulatory blood volume was decreased by approximately 25%, which was determined by the changes in hematocrit. Plasma AVP levels were elevated to 10.3 ± 3.0 pmol/l and UAQP-2, 578 ± 200 fmol/mg creatinine (normal, 153 ± 28) at the hospitalization. When hyperglycemia was improved by the intravenous infusion of a small dose of insulin plus fluid administration, both plasma AVP and UAQP-2 promptly decreased to 1.2 ± 0.2 pmol/l and 252 ± 29 fmol/mg creatinine on day 7, respectively. These alterations were concomitant with the recovery of circulatory blood volume. In the present study, UAQP-2, in addition to plasma AVP, indicates circulatory blood volume depletion, and the changes in UAQP-2 estimates the AVP-dependent recovery of circulatory blood volume during the therapeutic period in the patients with diabetic ketoacidosis.

          Related collections

          Most cited references 1

          • Record: found
          • Abstract: not found
          • Article: not found

          Electrical conductivity measurements from the GISP2 and GRIP Greenlandice cores


            Author and article information

            S. Karger AG
            May 2002
            02 May 2002
            : 91
            : 1
            : 167-169
            Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical School, Tochigi, Japan
            57622 Nephron 2002;91:167–169
            © 2002 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            Page count
            Figures: 1, References: 14, Pages: 3
            Self URI (application/pdf):
            Short Communication


            Comment on this article